Letteratura scientifica selezionata sul tema "Cisplatin"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Cisplatin".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Cisplatin"
ATAMAN, J. E., e D. BAXTER-GRILLO. "MORPHOLOGICAL EVALUATION OF CISPLATIN-INDUCED TESTICULAR DAMAGE IN WISTAR RATS". Nigerian Journal of Life Sciences (ISSN: 2276-7029) 4, n. 1 (17 marzo 2022): 16–25. http://dx.doi.org/10.52417/njls.v4i1.151.
Testo completoMonroe, Jerry D., Denis Hodzic, Matthew H. Millay, Blaine G. Patty e Michael E. Smith. "Anti-Cancer and Ototoxicity Characteristics of the Curcuminoids, CLEFMA and EF24, in Combination with Cisplatin". Molecules 24, n. 21 (29 ottobre 2019): 3889. http://dx.doi.org/10.3390/molecules24213889.
Testo completoHeiserman, James Patrick, Zenab Minhas, Elahe Nikpayam e Dong-Joo Cheon. "Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines". International Journal of Molecular Sciences 24, n. 16 (10 agosto 2023): 12638. http://dx.doi.org/10.3390/ijms241612638.
Testo completoCHEN, PING, QING-SHENG WU, YA-PING DING e ZI-CHUN ZHU. "PREPARATION OF CISPLATIN COMPOSITE MICRO/NANOFIBERS AND ANTITUMOR ACTIVITY IN VITRO AGAINST HUMAN TUMOR spc-a-1 CELLS". Nano 06, n. 04 (agosto 2011): 325–32. http://dx.doi.org/10.1142/s1793292011002688.
Testo completoMoon, Hyeon-Min, Jin-Sung Park, Il-Buem Lee, Young-Im Kang, Hae Jun Jung, Dongju An, Yumi Shin et al. "Cisplatin fastens chromatin irreversibly even at a high chloride concentration". Nucleic Acids Research 49, n. 21 (23 novembre 2021): 12035–47. http://dx.doi.org/10.1093/nar/gkab922.
Testo completoKarayay, Betül, Heidi Olze e Agnieszka J. Szczepek. "Degranulation of Murine Resident Cochlear Mast Cells: A Possible Factor Contributing to Cisplatin-Induced Ototoxicity and Neurotoxicity". International Journal of Molecular Sciences 24, n. 5 (27 febbraio 2023): 4620. http://dx.doi.org/10.3390/ijms24054620.
Testo completoATAMAN, J. E., e A. A. A. OSINUBI. "EFFECTS OF ETHANOLIC LEAF EXTRACT OF NEWBOULDIA LAEVIS (P. BEAUV) ON CISPLATIN-INDUCED CHANGES ON TESTICULAR AND BLOOD PARAMETERS OF WISTAR RATS". Nigerian Journal of Life Sciences (ISSN: 2276-7029) 4, n. 1 (17 marzo 2022): 26–36. http://dx.doi.org/10.52417/njls.v4i1.152.
Testo completoKumar, Gopal, Malvika H. Solanki, Xiangying Xue, Rachel Mintz, Swati Madankumar, Prodyot K. Chatterjee e Christine N. Metz. "Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity". American Journal of Physiology-Renal Physiology 313, n. 2 (1 agosto 2017): F339—F350. http://dx.doi.org/10.1152/ajprenal.00688.2016.
Testo completoAbedini Nazari, Najmeh, Behnam Omidi Sarajar, Seyedeh Zohreh Azarshin, Fatemeh Javani Jouni, Zahra Razzaghi e Jaber Zafari. "Overcoming Cisplatin’s Challenges: A Promising Future in Cancer Care; A Comprehensive Review". International Journal of Medical Toxicology and Forensic Medicine 13, n. 04 (28 gennaio 2024): 43478. http://dx.doi.org/10.32598/ijmtfm.v13i4.43478.
Testo completoSolanki, Malvika H., Prodyot K. Chatterjee, Madhu Gupta, Xiangying Xue, Andrei Plagov, Margot H. Metz, Rachel Mintz, Pravin C. Singhal e Christine N. Metz. "Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation". American Journal of Physiology-Renal Physiology 307, n. 4 (15 agosto 2014): F369—F384. http://dx.doi.org/10.1152/ajprenal.00127.2014.
Testo completoTesi sul tema "Cisplatin"
Amaral, Catia Lira do. "Efeito do resveratrol na nefrotoxicidade induzida pela cisplatina em ratos". Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/60/60134/tde-22052007-090133/.
Testo completoResveratrol (Res), a polyphenolic present in red wine, is known to possess potent antioxidant properties. The ability of resveratrol to protect against the nephrotoxicity of the antineoplastic agent cisplatin (cDDP) was evaluated in rats. The animals were treated with Res (25 mg/Kg body weight, ip., single dose) 30 minutes before administration of cDDP (5 mg/Kg body weight, ip., single dose) and then, sacrificed in 2 or 5 days followed by the treatment. After 5 days with resveratrol administration, the enhanced serum creatinine levels, urinary volume and urinary protein, which are indicative of renal injury, shown a significant reduction (p < 0.05). The cisplatintreated rats presented a tubular cell necrosis and increase immunostaining for ED1 and T-lymphocytes in the renal cortex and outer medulla. Those alterations were less intense in animals treated with resveratrol. After 2 days, administration of cisplatin to rats induced a higher malondialdehyde levels (MDA), and reduction in glutathione (GSH) concentrations in kidney tissue that were not prevented by resveratrol. In this study, the results indicate that resveratrol treatment attenuated the functional, histological and immunohistochemical renal alterations induced by cisplatin. The protect effect is relatated to the decrease of cells infiltrated at kidney tissue.
Santos, Graciela Cristina dos [UNESP]. "Avaliação do efeito protetor do urucum e da bixina sobre a genotoxicidade induzida pelo antitumoral cisplatina em células da linhagem PC12". Universidade Estadual Paulista (UNESP), 2008. http://hdl.handle.net/11449/100973.
Testo completoUniversidade Estadual Paulista (UNESP)
A neuropatia induzida por drogas quimioterápicas é uma complicação no tratamento do câncer e outras doenças por ser freqüentemente dolorosa e requerer a interrupção da terapia. O antitumoral cisplatina é comumente usado contra muitas formas de câncer há aproximadamente 40 anos. Entretanto, sua aplicação é associada a muitos efeitos tóxicos, como neurotoxicidade, nefrotoxicidade, perda da audição e vômitos. Estes efeitos adversos têm levado ao desenvolvimento de agentes específicos para amenizar a toxicidade do fármaco. Alguns estudos sugerem que a administração de antioxidantes é capaz de reduzir os danos e proteger os tecidos. Dessa forma, os carotenóides são mais uma opção a ser avaliada, pois são considerados eficazes agentes antioxidantes. O urucum é uma fonte natural de corantes vermelhos e além da bixina (fração lipossolúvel do extrato), estão presentes nas suas sementes, outros carotenóides, como a norbixina, o bcaroteno, a criptoxantina, a luteína e a zeaxantina. Neste estudo, foi avaliada a genotoxicidade e a antigenotoxicidade do urucum e da bixina sobre a toxicidade induzida pelo antitumoral cisplatina em culturas de células PC12. A citotoxicidade foi determinada pelo método do MTT, a frequência de danos cromossômicos pelo Teste do Micronúcleo e a extensão de danos primários ao DNA pelo Ensaio do Cometa. O urucum e a bixina foram avaliados preliminarmente quanto a sua genotoxicidade. O urucum nas concentrações 0,2, 0,5 e 1,0 mg/mL e a bixina nas concentrações 0,05, 0,08 e 0,10 mg/mL não foram citotóxicos e nem genotóxicos às células PC12. Assim, essas concentrações foram utilizadas nos experimentos para verificar a proteção do urucum e da bixina contra os danos induzidos pela cisplatina. Embora o efeito protetor do urucum e da bixina não tenha sido evidente nos resultados obtidos pelo Ensaio do Cometa, eles se mostraram...
The neuropathy induced by chemotherapeutic drugs is a complication in the treatment of cancer and other diseases, because it is often painful and requires discontinuation of the therapy. Cisplatin has been commonly used against many forms of cancer for approximately 40 years. However, its application is associated with many toxic effects such as neurotoxicity, nephrotoxicity, hearing loss and vomiting. These adverse effects have led to the development of specific agents to lessen the toxicity of the drug. Some studies have suggested that the administration of antioxidants is able to reduce the damage and protect the tissues. Thus, the carotenoids are one more option to be evaluated, because they are considered to be effective antioxidants. Annatto is a natural source of red dyes and pigments and in addition to bixin (liposoluble fraction of the extract), other carotenoids are present in its seeds, such as norbixin, B-carotene, cryptoxanthin, lutein and zeaxanthin. In the present study, the genotoxicity and antigenotoxicity of annatto and bixin on the cisplatin induced-toxicity in PC12 cell cultures was assessed. Cytotoxicity was determined by the MTT assay, chromosomal damage by the Micronucleus test and the extent of primary damage to the DNA by the Comet assay. Annatto and bixin were first assessed with respect to their genotoxicity. Annatto concentrations of 0.2, 0.5 and 1.0 mg/ml and bixin concentrations of 0.05, 0.08 and 0.10 mg/ml were neither cytotoxic nor genotoxic to the PC12 cells. Thus, these concentrations were used in experiments to verify the protective effect of annatto and bixin against damage induced by cisplatin. Although the protective effect of annatto and bixin was not evident in the results obtained by the Comet assay, effective inhibition of the chromosomal damage (Micronucleus test) induced by cisplatin was shown. Annatto and bixin protected... (Complete abstract click electronic access below)
Santos, Graciela Cristina dos. "Avaliação do efeito protetor do urucum e da bixina sobre a genotoxicidade induzida pelo antitumoral cisplatina em células da linhagem PC12 /". Araraquara : [s.n.], 2008. http://hdl.handle.net/11449/100973.
Testo completoAbstract: The neuropathy induced by chemotherapeutic drugs is a complication in the treatment of cancer and other diseases, because it is often painful and requires discontinuation of the therapy. Cisplatin has been commonly used against many forms of cancer for approximately 40 years. However, its application is associated with many toxic effects such as neurotoxicity, nephrotoxicity, hearing loss and vomiting. These adverse effects have led to the development of specific agents to lessen the toxicity of the drug. Some studies have suggested that the administration of antioxidants is able to reduce the damage and protect the tissues. Thus, the carotenoids are one more option to be evaluated, because they are considered to be effective antioxidants. Annatto is a natural source of red dyes and pigments and in addition to bixin (liposoluble fraction of the extract), other carotenoids are present in its seeds, such as norbixin, B-carotene, cryptoxanthin, lutein and zeaxanthin. In the present study, the genotoxicity and antigenotoxicity of annatto and bixin on the cisplatin induced-toxicity in PC12 cell cultures was assessed. Cytotoxicity was determined by the MTT assay, chromosomal damage by the Micronucleus test and the extent of primary damage to the DNA by the Comet assay. Annatto and bixin were first assessed with respect to their genotoxicity. Annatto concentrations of 0.2, 0.5 and 1.0 mg/ml and bixin concentrations of 0.05, 0.08 and 0.10 mg/ml were neither cytotoxic nor genotoxic to the PC12 cells. Thus, these concentrations were used in experiments to verify the protective effect of annatto and bixin against damage induced by cisplatin. Although the protective effect of annatto and bixin was not evident in the results obtained by the Comet assay, effective inhibition of the chromosomal damage (Micronucleus test) induced by cisplatin was shown. Annatto and bixin protected... (Complete abstract click electronic access below)
Orientador: Maria de Lourdes Pires Bianchi
Coorientador: Antonio Cardozo dos Santos
Banca: Alessandro de Oliveira Rios
Banca: Daisy Maria Fávero Salvadori
Banca: João Bosco Faria
Banca: Cecilia Rodrigues Silva
Doutor
Kullmann, Maximilian [Verfasser]. "Identifying intracellular cisplatin interaction partners and assessing their contribution to cisplatin resistance / Maximilian Kullmann". Bonn : Universitäts- und Landesbibliothek Bonn, 2016. http://d-nb.info/111988876X/34.
Testo completoHadi, Sutopo. "The chemistry of cisplatin metabolites /". [St. Lucia, Qld.], 2007. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe19800.pdf.
Testo completoZhang, Jin-Gang. "Cisplatin nephrotoxicity : mechanisms and antidotes". Thesis, University of Liverpool, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307635.
Testo completoCastro, João Humberto Teotônio de [UNESP]. "Avaliação do espermograma de cães submetidos à administração de cisplatina". Universidade Estadual Paulista (UNESP), 2007. http://hdl.handle.net/11449/89030.
Testo completoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
A correta orientação do Médico Veterinário, aos proprietários de cães, usados com finalidades reprodutivas, submetidas à quimioterapia com cisplatina, é importante na medida que este agente citostático age nas células em constante divisão, podendo ser citotóxicos para as células germinativas testiculares. O objetivo desse trabalho foi avaliar a qualidade espermática através do espermograma de cães que receberam cisplatina em diferentes momentos de análise espermática. A dose utilizada foi de 70 mg/mø, em intervalos de 21 dias, totalizando 4 infusões. Os cães foram divididos em dois grupos de 4 animais cada, sendo que um dos grupos recebeu a quimioterapia e o protocolo de diurese para proteção renal, já o grupo controle não recebeu a cisplatina, estando sujeito apenas aos fatores ambientais. Os resultados obtidos demonstraram que a cisplatina influenciou na qualidade espermática de cães, pois elevou as patologias maiores e totais acima do aceitável para cães aptos a reprodução. Portanto, infere-se que este citostático possa acarretar alterações morfofuncionais nos túbulos seminíferos e conduto epididimário.
The correct veterinary`s orientation for male dogs` owners used for reproduction goals, undergone cisplatin administration, is important because of this cistostatic act in cell with frequently proliferation, and could to cause germ cell injury. The objections of this experiment was to analysis the sperm quality through dogs` spermogram that received cisplatin`s infusions. The dose used was 70 mg/mø in 21 days periods, with 4 infusion in total. The dogs were divided in 2 groups with 4 animal each one. One of the groups received all the diuresys protocol (to protect the kidney) and the citostatic. And the other control group just didn`t receive the cisplatin infusion to know the real action of cisplatin effects without environmental stresses. The results show that cisplatin influence at the sperm quality in the dogs, because it elevated the major and total defects above that would be acceptable for competent dog to reproduct. It could deduct that cisplatin cause phisiologic alteration in the testis and epididymis.
Oliva, Carlos Alfredo Calpa [UNESP]. "Hemograma e teores séricos de Na, K, Mg, Ca e P de cães hígidos submetidos à administração de cisplatina". Universidade Estadual Paulista (UNESP), 2007. http://hdl.handle.net/11449/89087.
Testo completoA cisplatina é um fármaco antineoplásico utilizado como adjuvante no tratamento de diversas neoplasias. Neste estudo foram avaliados o hemograma e os teores de sódio, potássio, magnésio, cálcio e fósforo do soro sanguíneo de cães submetidos à terapia com cisplatina. Foram utilizados oito cães, machos, sem raça definida, com 10 a 15 kg de peso, clinicamente sadios. Os cães foram distribuídos em dois grupos, contendo 4 animais cada, sendo que os animais do grupo 1 receberam cisplatina e aqueles do grupo 2 não receberam cisplatina. Os cães do grupo 1 receberam quimioterapia e protocolo de diurese para proteção renal, já o grupo controle 2 não recebeu a cisplatina, estando sujeito apenas aos fatores ambientais. Os animais do grupo 1 foram submetidos a quatro sessões de quimioterapia com cisplatina na dose de 70mg/mø, administrada por via intravenosa, durante 20 minutos, no intervalo de 21 dias. Antes da administração da cisplatina, realizou-se fluidoterapia com solução fisiológica a 0,9% na dose de 25mL/kg/hora, por via intravenosa, durante duas horas, e depois por mais uma hora. Todos os animais receberam metoclopramida na dose de 2mg/kg, por via intravenosa, 15 minutos antes da administração da cisplatina e furosemida na dose de 2 mg/kg, por via intravenosa, 5 minutos após administração de metoclopramida. As amostras foram processadas e analisadas antes de cada sessão de quimioterapia. Os resultados mostraram que não houve diferença significativa entre os grupos para as contagens de hemácias, concentração de hemoglobina, hematócrito e contagem de leucócitos, mesmo assim as concentrações séricas de eletrólitos mantiveram-se dentro dos padrões da normalidade. Os resultados obtidos podem ser indicativos de que o protocolo empregado para o grupo 1 se mostrou efetivo para manter as características do hemograma e a concentração sérica dos eletrólitos.
The cisplatin is an antineoplasic drug used like adjunct treatment of various neoplasms. In this study, one evaluated the hemogram and sodium, potassium, magnesium, calcium and phosphorus levels in the dogs` blood under administration of cisplatin. One used 8 male dogs, with no definite race, weighing from 10 to 15 kilograms, and clinically healthy. The dogs were divided into two groups of 4 animals each, being group 1 treated with cisplatin and group 2 with no cisplatin. Group 1 received chemotherapy and the diurese protocol for kidney protection, group 2 did not receive cisplatin, being exposed only to the environmental factors. The animals from group 1 were submitted to four chemotherapy sessions with cisplatin 70mg/m2 administered intravenously for 20 minutes, in a 21 days interval before the cisplatin administration, one carried out a fluidotherapy with physiologic solution 0,9% on a dosage of 25mg/kg/hour intravenously during 2 hours, and posteriorly for one more hour. All the animals received methoclopramid intravenously on a dosage of 2mg/kg, 15 minutes before the cisplatin and furosemide administration on a 2mg/kg dosage, 5 minutes before the cisplatin infusion. The evaluation of the hemogram and the electrolytes levels above mentioned were done before each chemotherapy session. The results demonstrate that there were no significant differences among the groups for red blood cells counting, hemoglobin concentration, hematocrit and leucocytes counting, but still, the electrolytes seric concentration maintained itself in a normal standard. The results obtained may indicate that the protocol employed for group 1 showed efficiency to maintain the characteristics of the hemogram and the electrolytes seric concentration.
Li, Yan Julia. "Cisplatin-induced cytotoxicity in MDCK cells". Thesis, University of Ottawa (Canada), 2002. http://hdl.handle.net/10393/6408.
Testo completoBrock, Penelope. "Cisplatin toxicity in infants and children /". Leuven : Leuven University Press, 1994. http://www.gbv.de/dms/bs/toc/190814756.pdf.
Testo completoLibri sul tema "Cisplatin"
Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Syracuse, N.Y: Bristol-Myers Oncology Division, 1985.
Cerca il testo completoYoshihiro, Kikuchi, a cura di. Mechanism of cisplatin resistance and its circumvention. Commack, NY: Nova Science Publishers, 1998.
Cerca il testo completoChu, Wendy. Mechanism of cisplatin resistance inhuman malignant melanoma. Ottawa: National Library of Canada, 1998.
Cerca il testo completoMerazga, Yamina. Aspects of the interaction between cisplatin and renal glutathione. Uxbridge: Brunel University, 1990.
Cerca il testo completo1946-, Lippert Bernhard, a cura di. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Zürich: Verlag Helvetica Chimica Acta, 1999.
Cerca il testo completoMorley, Christopher. Analogues of cisplatin from diamino carbohydrates and related compounds. Norwich: University of East Anglia, 1986.
Cerca il testo completoEvans, Dyfed Llyr. The induction of apoptosis by the anticancer agent cisplatin. Manchester: Universityof Manchester, 1994.
Cerca il testo completoLaurell, Göran. Ototoxicity of the anticancer drug cisplatin: Clinical and experimental aspects. Stockholm, Sweden: Distributed by Almqvist & Wiksell Periodical Co., 1991.
Cerca il testo completoInstitut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom: Nutzenbewertung gemäß § 35a SGB V. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2017.
Cerca il testo completoBryant, Eric Edward. Systems Genetics of DNA Damage Tolerance – Cisplatin, RAD5 & CRISPR-mediated Nonsense. [New York, N.Y.?]: [publisher not identified], 2019.
Cerca il testo completoCapitoli di libri sul tema "Cisplatin"
Rosenberg, Barnett. "Platinum Complexes for the Treatment of Cancer: Why the Search Goes On". In Cisplatin, 1–27. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch1.
Testo completoAno, Susan O., Zsuzsanna Kuklenyik e Luigi G. Marzilli. "Structure and Dynamics of Pt Anticancer Drug Adducts from Nucleotides to Oligonucleotides as Revealed by NMR Methods". In Cisplatin, 247–91. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch10.
Testo completoChen, Yu, Zijian Guo e Peter J. Sadler. "195Pt- and 15N-NMR Spectroscopic Studies of Cisplatin Reactions with Biomolecules". In Cisplatin, 293–318. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch11.
Testo completoBau, Robert, e Michal Sabat. "Structural Aspects of Pt-Purine Interactions: From Models to DNA". In Cisplatin, 319–37. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch12.
Testo completoReedijk, Jan, e Jan Maarten Teuben. "Platinum-Sulfur Interactions Involved in Antitumor Drugs, Rescue Agents, and Biomolecules". In Cisplatin, 339–62. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch13.
Testo completoAppleton, Trevor G. "Diammine- and Diamineplatinum Complexes with Non-Sulfur-Containing Amino Acids and Peptides". In Cisplatin, 363–76. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch14.
Testo completoLippert, Bernhard. "Platinum Blues: On the Way toward Unraveling a Mystery". In Cisplatin, 377–403. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch15.
Testo completoRandaccio, Lucio, e Ennio Zangrando. "Heteronuclear PtII Complexes with Pyrimidine Nucleobases". In Cisplatin, 405–28. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch16.
Testo completoNatile, Giovanni, Francesco P. Intini e Concetta Pacifico. "Diplatinum(III) Complexes: Chemical Species More Widely Spread Than Suspected". In Cisplatin, 429–53. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch17.
Testo completoMatsumoto, Kazuko. "Inorganic and Organometallic Chemistry of Cisplatin-Derived Diplatinum(III) Complexes". In Cisplatin, 455–75. Zürich: Verlag Helvetica Chimica Acta, 2006. http://dx.doi.org/10.1002/9783906390420.ch18.
Testo completoAtti di convegni sul tema "Cisplatin"
Absar, Saheem, Mujibur Khan, Kyle Edwards e David Calamas. "Electrospinning of Cisplatin-Loaded Cellulose Nanofibers for Cancer Drug Delivery". In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-37182.
Testo completoCamargo, Luana Cristina, Joao Paulo Figueiro Longo, Karen Letycia Rodrigues de Paiva, Marina Mesquita Simões, Thais Bergmann e Victor Carlos Mello da Silva. "Immunotherapy vaccines for triple-negative breast cancer and its influence on the tumor microenvironment". In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1024.
Testo completoLau, KingWun. "Brief summary of cisplatin nephrotoxicity". In International Conference on Biological Engineering and Medical Science (ICBIOMed2022), a cura di Gary Royle e Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669859.
Testo completoSoodvilai, Sirima, Sunhapas Soodvilai, Warayuth Sajomsang, Theerasak Rojanarata, Prasopchai Patrojanasophon e Praneet Opanasopit. "Chitosan Polymeric Micelles for Prevention of Cisplatin-Induced Nephrotoxicity and Anticancer Activity of Cisplatin". In ICBET 2020: 2020 10th International Conference on Biomedical Engineering and Technology. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3397391.3397438.
Testo completoLee, Chunman, Masao Sasai e Yoshiki Sawa. "Abstract 4452: Controlled release complex of cisplatin for mesothelioma: gamma-PGA/Cisplatin complex formulation". In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4452.
Testo completoLiang, Xiaobing, Michael D. Mueller e Jing Jie Yu. "Abstract 2982: Activation of checkpoint kinase Chk2 by cisplatin and its role in cisplatin resistance". In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2982.
Testo completoAbdullah, N., N. Al Balushi, S. Al-Bahlani, S. Dobretsov, I. Hassan, T. Sang, Y. Tamimi e I. Burney. "EP765 The effect of malformina1 on cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines". In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.816.
Testo completoLarisch, C., T. Markowiak, S. Golovchenko, P. Bednarski, K. Müller, C. Großer, H.-S. Hofmann e M. Ried. "Dosis-abhängige Cisplatin-Konzentration und -Eindringtiefe in humanes Lungengewebe bei Inkubation in hyperthermer Cisplatin-Lösung". In 32. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1771119.
Testo completoGupta, Vikas, Ashok Kumar Chauhan, Paramjeet Kaur, Anil Khurana, Yashpal Verma e Nupur Bansal. "Comparative evaluation of concomitant chemoradiation with weekly cisplatin and gemcitabine versus weekly cisplatin in the management of locally advanced carcinoma of uterine cervix". In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685264.
Testo completoRichards, Elizabeth J., William O. Cookson, Sanjay Popat e Miriam F. Moffatt. "Transcriptome Changes Accompanying Induced Cisplatin Resistance". In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4918.
Testo completoRapporti di organizzazioni sul tema "Cisplatin"
Turchi, John J. Proteomic Analysis of Cisplatin-Resistant Ovarian Cancer. Fort Belvoir, VA: Defense Technical Information Center, marzo 2004. http://dx.doi.org/10.21236/ada425620.
Testo completoTurchi, John. Proteomic Analysis of Cisplatin-Resistant Ovarian Concers. Fort Belvoir, VA: Defense Technical Information Center, marzo 2006. http://dx.doi.org/10.21236/ada462560.
Testo completoTurchi, John J. Proteomic Analysis of Cisplatin-Resistant Ovarian Concers. Fort Belvoir, VA: Defense Technical Information Center, marzo 2005. http://dx.doi.org/10.21236/ada463194.
Testo completoBalaji, Kethandapatti C. MT 2A Phosphorylation by PKC Mu/PKD Influences Chemosensitivity to Cisplatin in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, novembre 2008. http://dx.doi.org/10.21236/ada495664.
Testo completoAllworth, Ann E. The Role of Terbium and Gadolinium in Reversal of Cisplatin Resistance in Cultured Human Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, giugno 2001. http://dx.doi.org/10.21236/ada414791.
Testo completoMiao, Fang, Yaru Guo, Yan Yuan, Juzhou Chen e Yong Xin. Bevacizumab combined with pemetrexed plus carboplatin or cisplatin in the treatment of malignant pleural effusion of lung cancer : A meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, aprile 2022. http://dx.doi.org/10.37766/inplasy2022.4.0096.
Testo completoWang, Dandan, Shuaihang Hu, Kangdi Cao, Chenxi Qiao, Zhuo Wang e Wei Hou. Clinical efficacy and safety of Chinese herb injections combination with Docetaxel combined with cisplatin (DP) chemotherapy for advanced non-small cell lung cancer: A protocol for Bayesian network meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, settembre 2022. http://dx.doi.org/10.37766/inplasy2022.9.0081.
Testo completoLi, Qian, Hua Xiao, Ren-long Liang, Qian-ru Yu, De-qing Tian, Li-na Zhao, Wen-wen Wang e Xiao-jia Yong. Efficacy and safety of Cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, giugno 2020. http://dx.doi.org/10.37766/inplasy2020.6.0091.
Testo completoHealth hazard evaluation report: HETA-2009-0121-3106, evaluation of exposures to healthcare personnel from cisplatin during a mock interperitoneal operation, University Medical Center, Las Vegas, Nevada. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, marzo 2010. http://dx.doi.org/10.26616/nioshheta200901213106.
Testo completo